Eva Wesley

Biovalley Investments Partner (BIP) sold its entire stake in BIC Incubatori FVG to Innova, both Trieste-based firms and longtime users of the incubator. BIP will continue collaborating with Innova on investments. The deal lets BIP refocus on core biotech, hydrogen transport, and AI-driven medical technologies, including its ChemoMaker oncology robot, while Innova advances BIC's growth.

A CSIC-UMH study identifies heightened interferon signaling as a key factor in women's greater Alzheimer's vulnerability. Analysis of human brain tissue and animal models showed stronger immune activation, increased inflammation, and cognitive decline in females. Blocking this pathway reduced damage and improved memory, suggesting interferon modulation as a promising therapeutic strategy, pending future clinical validation.

Emily.AI, Quirónsalud's explainable AI medical device, became a global finalist at the AI for Good Summit 2026 after competing with 500+ projects. Developed in Catalonia, it personalizes oxygen therapy in real time, improving outcomes across care settings. With remote monitoring and automation, it enhances efficiency, supports SDGs, and reduces clinical workload while optimizing oxygen use.

Legend Biotech's stock reflects demand for innovative CAR-T cancer therapies. The US biotech focuses on commercializing Carvykti with partner Janssen while expanding its pipeline. Approved revenue supports research into additional indications and programs. Valuation depends on clinical progress, regulatory outcomes, and partnerships, with diversified trials helping balance risks typical of specialized cell therapy companies globally.

After a downturn, biotechnology is regaining attention as major pharmaceutical companies invest heavily in innovative platforms to offset patent losses and boost growth. Acquisitions are rising as a faster, lower-risk alternative to in-house research. Expanding cell therapy applications and undervalued biotech firms, including Mesoblast, signal potential opportunities in a renewed industry growth cycle.

Sartorius Stedim Biotech reported solid H1 2026 results, with revenue reaching €1.527 billion and EBITDA rising to €479 million. Growth was driven by recurring demand and equipment recovery, despite U.S. tariff-related adjustments. Customer compensation impacted reported sales, but the company confirmed full-year targets, expecting 6–10% revenue growth and an EBITDA margin above 31%.

The Indian pharmaceutical and biotechnology sector is transforming through acquisitions and innovation. Sun Pharma plans to acquire Innovcare Lifesciences to expand in nutritional supplements, and has also acquired Organon to strengthen its global presence. Meanwhile, Immuneel Therapeutics raised funds for cancer therapies. Together, these moves show consolidation and rising innovation across India's maturing health sector.

European stocks moved on earnings and broker actions. Evotec, BioGaia, Plus500, Pharming, Inwido, Amundi and Julius Baer rallied on upgrades, strong results, growth outlooks and strategic moves. Meanwhile Vitrolife, Demant, Publicis, Akzo Nobel, Siltronic, Pandora and Schaeffler declined due to weak margins, cautious guidance, downgrades, or profit-taking. Investors reacted to visibility changes and demand expectations.

Chinese pharmaceutical companies are rapidly advancing, producing drugs faster and cheaper while expanding globally through partnerships and Basel-based headquarters. Once focused on generics, they now rival major Western firms in innovative treatments, including cancer drugs. Despite strong R&D and deals, challenges remain in Europe's complex regulatory systems, while U.S. policies increase scrutiny on Chinese biotech collaborations.

Recent funding rounds highlight strong investment in biotech, industrial tech, agriculture, and deep tech. Brenus Pharma raised €11 million to advance cancer immunotherapy, while Pelico scales AI-driven manufacturing optimization. Aptimiz improves farm management, Remedy Metals targets rare earth refining, and Muodim develops non-invasive imaging technologies for industrial and infrastructure applications globally across diverse critical sectors.